Drug intelligence / Profile preview

TGI

Development stage: Unknown
Lead developer: Shandong Cancer Hospital
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

**TGI** is a multiagent intravenous chemotherapy regimen used in the context of recurrent or refractory pediatric rhabdomyosarcoma. In the registered Shandong Cancer Hospital study context, TGI is interpreted as **nab-paclitaxel + gemcitabine + irinotecan** and is administered as part of a treatment strategy with pazopanib and TGI/CIV chemotherapy. Nab-paclitaxel disrupts mitosis through microtubule stabilization, gemcitabine inhibits DNA synthesis, and irinotecan inhibits DNA topoisomerase I. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06816771))

Other names: TGI chemotherapyTGI regimen

Targets

DNA polymerase familyDNARNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on TGI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TGI.

Explore the full profile